ClinVar Miner

Submissions for variant NM_000179.3(MSH6):c.2410_2411insT (p.Lys804fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV004018163 SCV004848645 likely pathogenic Lynch syndrome 2022-04-01 criteria provided, single submitter clinical testing The p.Lys804IlefsX16 variant in MSH6 has not been reported in individuals with MSH6-associated cancers or in large population databases. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 804 and leads to a premature termination codon 16 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the MSH6 gene is an established disease mechanism in autosomal dominant Lynch syndrome. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant Lynch syndrome. ACMG/AMP Criteria applied: PVS1, PM2_Supporting.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.